Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 shortened-interval treatment in blepharospasm
2007-000697-23Phase 2Terminated
- Sponsor
- Merz
- Start
- Jun 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in idiopathic blepharospasm (BEB), sponsored by Merz. Started Jun 2007; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
idiopathic blepharospasm (BEB)
Beyond the preview
Go deeper on 2007-000697-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000697-23.